Zobrazeno 241 - 250
of 502
pro vyhledávání: ''
Publikováno v:
Annals of the Rheumatic Diseases. 79:1573.1-1573
Background:The nocebo phenomenon, the opposite of placebo, defined as unfavourable changes in a patient’s symptoms or condition resulting from negative anticipations to treatment and possibly leading to suboptimal outcomes and non- adherence, is mo
Autor:
J. Fernández-Leroy, Gemma Bonilla, J. Loricera, A. López Robles, I. Villa-Blanco, Iván Cabezas-Rodríguez, M. Lopez Corbeto, Ricardo Blanco, A. Urruticoechea-Arana, E. C. Cervantes Pérez, T. Pérez Sandoval, J.M. Blanco, L. M. Arboleya Rodríguez, C. Ojeda-Garcia, Ivan Castellví, Ángel García-Aparicio, Samantha Rodríguez-Muguruza, Susana Romero-Yuste, D. Palma Sanchez, Santos Castañeda, J. L. Andréu Sánchez, C. Hidalgo, Miguel A. González-Gay, P. Morales-Garrido, Raquel Almodóvar, I. Hernández-Rodriguez, Francisco Ortiz-Sanjuán, Carmen Carrasco-Cubero, R. Melero, A. Juan-Mas, C. González-Montagut Gómez, S. Rodrigez-Garcia, L. Pérez Albaladejo, S. Fernández, Eva Salgado-Pérez, L. Exposito-Perez, C. Fernández-López, Patricia Carreira, C. Fernández-Díaz, C. Aguilera Cros, Blanca Garcia-Magallon, A. García-Valle, J. De Dios-Jiménez Aberásturi, S. Castro, P. Vela-Casasempere, J. Narváez, Rosa Expósito, C. Peralta-Ginés, N. Del-Val, S. Ordoñez, A. Ruibal-Escribano, O. Maiz-Alonso, R. Castellanos-Moreira, Noelia Alvarez-Rivas, Natalia Mena-Vázquez, A. Devicente-Delmas, E. García-Fernández, Manuel Moreno, M. Rodíguez-Gómez, R. López-Sánchez
Publikováno v:
Annals of the Rheumatic Diseases. 79:972.1-972
Background:Interstitial Lung Disease (ILD) is an extra-articular complication of rheumatoid arthritis (RA) that is associated with increased morbidity and mortality. Conventional disease-modifying drugs (DMARDs) such as methotrexate (MTX) have been i
Autor:
Silje W Syversen, G. L. Goll, Espen A Haavardsholm, K. K. Jørgensen, Inge C. Olsen, Joseph O. Sexton, T.K. Kvien, Jørgen Jahnsen, Nils Bolstad, C. Mørk, David J. Warren, M. K. Brun, J. E. Gehin, Øystein Sandanger
Publikováno v:
Annals of the Rheumatic Diseases. 79:12-12
Background:A lack or loss of response to TNFα inhibitors (TNFi) has been associated with low serum drug levels and formation of anti-drug antibodies (ADAb). Therapeutic drug monitoring (TDM), an individualised treatment strategy based on regular ass
Publikováno v:
Annals of the Rheumatic Diseases. 79:454.3-454
Background:Pegloticase is a PEGylated biologic for uncontrolled gout that has well-established efficacy. However, anti-drug antibody (ADA) development causes many patients to discontinue treatment before receiving the full therapeutic course.1ADAs bi
Publikováno v:
Annals of the Rheumatic Diseases. 79:1176.3-1176
Background:Persistence rates of biologic disease modifying antirheumatic drugs (bDMARDs), which refer to the duration of time from initiation to discontinuation or switch of therapy, have been shown to vary considerably depending on the country, type
Publikováno v:
Annals of the Rheumatic Diseases. 79:1596.1-1596
Background:Dermatomyositis (DM) is a systemic, autoimmune disease affecting the skin and proximal skeletal muscles. A subset of DM patients present with subclinical or resolved muscle involvement but continue to have skin disease. In these cases, fir
Publikováno v:
Annals of the Rheumatic Diseases. 79:650.1-650
Background:Baricitinib is considered as a specific JAK1/2 inhibitor. While a number of randomized controlled trials have reported on the clinical efficacy and safety profile of baricitinib in rheumatoid arthritis (RA) patients, clinical data for RA p
Publikováno v:
Annals of the Rheumatic Diseases. 79:1690-1690
Background:Psoriatic arthritis (PsA) is associated with a high burden of disease and an increased risk of comorbidities. Recent data suggest that patients with moderate PsA benefit most from apremilast (APR) treatment.1Results from an earlier analysi
Autor:
Samina A. Turk, D. Marsman, Maarten Boers, E. N. Griep, Calin D. Popa, L. Van Boheemen, Wouter H Bos, M. Starmans, M. H. Van Beers Tas, Michael T. Nurmohamed, A.M. van Sijl, D. van Schaardenburg
Publikováno v:
Annals of the Rheumatic Diseases. 79:1415.2-1416
Background:Persons at high risk for developing rheumatoid arthritis (RA) may benefit from a low-risk pharmacological intervention aimed at primary prevention. Statins are safe and widely-used drugs; previous studies demonstrated disease-modifying eff
Autor:
Michael W. Beresford, Jennifer C Davies, Angela Midgley, Ian N. Bruce, Sean Joseph Donohue, Christian M. Hedrich
Publikováno v:
Annals of the Rheumatic Diseases. 79:352.1-352
Background:Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease. Approximately 30% of SLE patients develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably pr